S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 2.71 HKD 1.5% Market Closed
Market Cap: 8B HKD

Operating Margin
SSY Group Ltd

23.4%
Current
23%
Average
6.6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
23.4%
=
Operating Profit
1.4B
/
Revenue
5.8B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
HK
SSY Group Ltd
HKEX:2005
8B HKD
23%
US
Eli Lilly and Co
NYSE:LLY
722.9B USD
40%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
359B USD
26%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
45%
CH
Roche Holding AG
SIX:ROG
206.2B CHF
33%
CH
Novartis AG
SIX:NOVN
185.9B CHF
33%
UK
AstraZeneca PLC
LSE:AZN
161.7B GBP
24%
US
Merck & Co Inc
NYSE:MRK
200.1B USD
34%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
11%
US
Pfizer Inc
NYSE:PFE
136.3B USD
27%

SSY Group Ltd
Glance View

Market Cap
8B HKD
Industry
Pharmaceuticals

SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.

Intrinsic Value
4.89 HKD
Undervaluation 45%
Intrinsic Value
Price
S
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
23.4%
=
Operating Profit
1.4B
/
Revenue
5.8B
What is the Operating Margin of SSY Group Ltd?

Based on SSY Group Ltd's most recent financial statements, the company has Operating Margin of 23.4%.

Back to Top